#82 -The Future of Chronic Spontaneous Urticaria Treatments (Dupilumab, Remibrutinib, and Barzolvolimab.)

There’s never been a better time to be a CSU patient, with cutting-edge therapies and revolutionary treatments just around the corner. As research accelerates, new and promising options that could significantly improve the quality of life for those living with Chronic Spontaneous Urticaria are coming to market.

In this episode, Dr. Matthew Zirwas joins us to discuss the latest advancements in treating CSU, offering invaluable insights into both current and emerging treatment options. With his extensive experience and patient-centred approach, Dr. Zirwas breaks down the complexities of CSU and highlights how these new therapies can make a real difference.

This podcast was made in partnership with Allergy & Asthma Network. We thank Novartis for sponsoring this podcast.

What We Cover in Our Episode About Emerging Chronic Spontaneous Urticaria Treatments:

• How Dr. Zirwas explains CSU to his patients: Discover the patient-friendly explanations that help demystify CSU and empower patients to learn more about their disease.
• When to start with a biologic: Learn about the decision-making process for initiating biologic therapies like Xolair (omalizumab) and when they are most appropriate.
• The new medications coming to market: Get an overview of the latest advancements, including:
  • Dupixent (dupilumab): A biologic administered via injection that targets key pathways in the inflammatory response.
  • Remibrutinib: A BTK (Bruton tyrosine kinase) inhibitor available as a pill that blocks a crucial enzyme in mast cell activation.
  • Barzolvolimab: A promising biologic that targets the C KIT receptor on mast cells to reduce their number.
• Shared decision-making with these medications: Explore strategies for choosing the most appropriate treatment in a rapidly evolving therapeutic landscape.
• Research into the underlying cause of CSU: What’s happening on the research front to uncover the root causes of CSU.

About Our Guest

Dr. Matthew Zirwas, MD, is a board-certified dermatologist and a nationally recognized expert in allergy patch testing, psoriasis, and eczema. He founded the Bexley Dermatology Research Clinic, offering patients access to the latest treatment options before they are widely available. Dr. Zirwas also serves as a dermatologic advisor for several companies, including ALL Laundry Detergent and Cerave, and contributes to Women’s Health Magazine. Learn more about Dr. Zirwas.

More resources about chronic spontaneous urticaria:

• Chronic Urticaria Management, Resources & Glossary of Terms: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/management-and-resources/
• What is Chronic Urticaria: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/
• More information about Omalizumab (Xolair): https://www.xolair.com/chronic-spontaneous-urticaria.html

Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.